Moreover, RGS treatment disrupted RAS/MEK/ERK and PI3K/AKT signaling in KRAS-mutant CRC cell lines and KRAS-mutant PDX tumor specimens. The gene discussed is MAP2K7; the disease is colorectal carcinoma.